{"@id":"https://bioecon.ru/technology/ai-driven-biomarker-discovery/","@type":"Technology","cluster":"diagnostics-medtech","formats":{"html":"https://en.bioecon.ru/technology/ai-driven-biomarker-discovery/","json":"https://en.bioecon.ru/api/v1/technology/ai-driven-biomarker-discovery/index.json"},"id":"ai-driven-biomarker-discovery","industries":["diagnostics"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/diagnostics/"],"suppliers":["https://bioecon.ru/companies/schr-dinger/","https://bioecon.ru/companies/euphoria-retreat/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/biohaven/","https://bioecon.ru/companies/genmab/","https://bioecon.ru/companies/acadian-plant-health/","https://bioecon.ru/companies/allozymes/","https://bioecon.ru/companies/huazhi-rice-gene-technology/","https://bioecon.ru/companies/nthing/","https://bioecon.ru/companies/protera/"]},"maturity":null,"name":"AI-driven biomarker discovery","regions":["us","cn","eu"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-09-18","entity":"grail","kind":"vendor","urls":["https://grail.com/press-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting/","https://grail.com/press-releases/grail-reports-second-quarter-2026-financial-results/","https://investors.grail.com/node/8391/html","https://www.fiercebiotech.com/medtech/flying-solo-grail-will-cut-30-staff-and-narrow-its-rd-commercial-focus"]},{"date":"2026-09-18","entity":"caris-life-sciences","kind":"vendor","urls":["https://investor.carislifesciences.com/static-files/94e5ccde-41c7-4154-b11f-e19b56a4a5ec","https://last10k.com/sec-filings/cai/0002019410-26-000055.htm","https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer/","https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-introduces-ai-powered-molecular-insights-for-nsclc-patients/","https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance/","https://www.prnewswire.com/news-releases/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance-302843876.html"]}],"stages":[{"n":1,"title":"Cohort and biobank"},{"n":2,"title":"Population-scale measurement"},{"n":3,"title":"Model discovery and training"},{"n":4,"title":"Assay lock and validation"},{"n":5,"title":"Regulatory and coverage"},{"n":6,"title":"Clinical operation at scale"}],"summary":"Machine learning over population-scale molecular data that turns weak signals — methylation patterns, mutation signatures, multimodal profiles — into clinical biomarkers. The table carries two vendors with fully sourced dossier ledgers; the wider platform field is named in the note, not padded into the table.","url":"/technology/ai-driven-biomarker-discovery/","verified":"2026-09-18"}